1.A correlation of retinal lesion appearance and distribution to CD4 counts of patients with human immunodeficiency virus using ultrawide field scanning laser ophthalmoscope images
Anna Maria F. Payawal-Lucero ; Paolo S. Silva
Philippine Journal of Ophthalmology 2024;49(2):150-155
OBJECTIVE
To identify retinal lesions through ultrawide field (UWF) images and correlate their presence, size, location, and number with the immunologic status of individuals living with human immunodeficiency virus (HIV)
METHODSThis retrospective study reviewed UWF retinal images and CD4 counts of adult patients diagnosed with HIV. ImageJ software was used to annotate lesions and create heat maps. The distribution of lesions (hemorrhages, cotton wool spots, cytomegalovirus [CMV] lesions) was evaluated across 3 retinal zones: posterior pole, mid-periphery and far periphery. Statistical analyses were conducted using SAS version 9.4.
RESULTSThe study included 44 eyes of 23 male HIV patients, with a mean age of 35 ± 9.3 years, and a mean CD4 count of 74 ± 145 cells/mm³. HIV retinopathy was present in 24 (54.5%) eyes and CMV retinitis in 6 (13.6%) eyes. Among eyes with HIV-related findings (N=30), 8 (26.7%) had hemorrhages, 19 (63.3%) had cotton wool spots, and 7 (23.3%) had both. Eyes with HIV retinopathy had significantly low CD4 counts (17 vs. 25 cells/mm³, p=0.0398), and eyes with CMV retinitis had even lower CD4 counts (9 vs. 22 cells/mm³, p=0.0133). Lesion annotations showed that the mean area covered by hemorrhages was 0.47 mm² (97.9% in the posterior pole), cotton wool spots was 0.73 mm² (96.0% in the posterior pole), and CMV lesions was 22.89 mm² (37.9% in the posterior pole, 35.9% in the mid-periphery, and 26.1% in the far periphery).
CONCLUSIONHIV retinopathy findings are predominantly located within 10 mm of the foveal center, while over 62% of CMV lesions are present outside this zone. This highlights the importance of evaluating the retinal periphery in high-risk patients. Regular monitoring using UWF imaging is recommended for HIV-infected individuals with low CD4 counts, to detect vision-threatening conditions like CMV retinitis.
Human ; Hiv ; Retinal Hemorrhage
2.Retinal Toxicity Following the Injection Ganciclovir into Silicone Oil-filled Eye to Treat Acute Retinal Necrosis
Yeon Ji JO ; Seung Kwon CHOI ; Sun Ho PARK ; Jae Jung LEE ; Ji Eun LEE ; Sung Who PARK
Journal of the Korean Ophthalmological Society 2020;61(1):111-115
PURPOSE: To report a case of retinal toxicity after an intravitreal ganciclovir injection to treat acute retinal necrosis in an eye filled with silicone oil.CASE SUMMARY: A 56-year-old male presented with ocular pain and visual loss in his right eye. His best-corrected visual acuity was 20/25, inflammatory cells in the anterior chamber, multiple retinitis lesions and retinal vessel occlusions in the peripheral retina and vitreous opacity were showed. Acute retinal necrosis was suspected, anterior chamber polymerase chain reaction (PCR) test was done. Aciclovir 2,400 mg/day intravenously and ganciclovir 2.0 mg were administered by intravitreal injection. After 4 days, retinitis was worsened and PCR test was positive for varicella zoster virus. Ganciclovir intravitreal injections were increased twice a week. After 16 days, retinal detachment occurred, so scleral encircling, vitrectomy, laser photocoagulation, and silicone oil tamponade were conducted. Ganciclovir 1.0 mg was injected at the end of surgery. The patient's visual acuity decreased to hand motion, and multiple crystal deposits with multiple retinal hemorrhages were observed in the right eye the next day. Visual acuity did not recover and optical coherent tomography showed that the macula was thinned.CONCLUSIONS: Visual loss seemed to be related with the retinal toxicity of ganciclovir. The increased local concentration due to the silicone oil tamponade is thought to have caused the toxicity.
Acyclovir
;
Anterior Chamber
;
Ganciclovir
;
Hand
;
Herpesvirus 3, Human
;
Humans
;
Intravitreal Injections
;
Light Coagulation
;
Male
;
Middle Aged
;
Polymerase Chain Reaction
;
Retina
;
Retinal Detachment
;
Retinal Hemorrhage
;
Retinal Necrosis Syndrome, Acute
;
Retinal Vessels
;
Retinaldehyde
;
Retinitis
;
Silicon
;
Silicones
;
Visual Acuity
;
Vitrectomy
3.Bilateral Rhegmatogenous Retinal Detachments after Systemic Pazopanib Treatment
Sun Young RYU ; Soo Jung HONG ; Eun Jee CHUNG
Journal of the Korean Ophthalmological Society 2019;60(5):491-495
PURPOSE: A case of bilateral rhegmatogenous retinal detachment is reported after pazopanib treatment of a patient with breast angiosarcoma. CASE SUMMARY: A 53-year-old female presented with bleeding in a right breast mass prior to an emergency room visit. She was diagnosed with metastatic breast angiosarcoma after a breast mass biopsy. She was treated with paclitaxel and radiation therapy. Systemic pazopanib treatment was added to treat lung metastasis. After 3 weeks, she felt sudden floaters in her right eye. In her fundus examination, there was vitreous hemorrhage, but no retinal detachment was noted. Five weeks later, she visited the clinic for a bilateral temporal visual field defect. A fundus examination showed bilateral retinal detachments with superonasal retinal tears. Both the patient and her family did not want surgery for her systemic condition because of her terminal cancer. CONCLUSIONS: Retinal detachment has been reported as a rare complication after systemic pazopanib treatment, but there has been no previous report in the Republic of Korea, therefore this is the first case of bilateral retinal detachments after systemic pazopanib treatment.
Biopsy
;
Breast
;
Emergency Service, Hospital
;
Female
;
Hemangiosarcoma
;
Hemorrhage
;
Humans
;
Lung
;
Middle Aged
;
Neoplasm Metastasis
;
Paclitaxel
;
Republic of Korea
;
Retinal Detachment
;
Retinal Perforations
;
Retinaldehyde
;
Visual Fields
;
Vitreous Hemorrhage
4.Diabetic Nephropathy in Type 2 Diabetic Retinopathy Requiring Panretinal Photocoagulation
Minji HA ; Seung Yong CHOI ; Mirinae KIM ; Jong Kyeong NA ; Young Hoon PARK
Korean Journal of Ophthalmology 2019;33(1):46-53
PURPOSE: To investigate the risk factors of diabetic nephropathy in patients with diabetic retinopathy requiring panretinal photocoagulation (PRP) and the visual prognosis. METHODS: A retrospective review of electronic medical records was conducted at Seoul St. Mary's Hospital, comprising 103 patients with type 2 diabetes mellitus and diabetic retinopathy who underwent PRP from 1996 to 2005. Patients with type 1 diabetes mellitus, non-diabetic renal disease, non-diabetic retinal disease, visually significant ocular disease, high-risk proliferative diabetic retinopathy, and advanced diabetic retinopathy were excluded. The patients were divided into three groups: no nephropathy (group 1, n = 45), microalbuminuria (group 2, n = 16), and advanced nephropathy (group 3, n = 42). Duration of diagnosis of retinopathy and nephropathy, glycosylated hemoglobin, visual acuity, complications, and treatment history were investigated. RESULTS: The mean glycosylated hemoglobin of group 3 (8.4 ± 1.2) was higher than that of group 1 (7.7 ± 1.0) or group 2 (7.7 ± 1.0) (p = 0.04). Mean interval from PRP to diagnosis of nephropathy was 8.8 ± 6.0 years in group 2 and 8.7 ± 4.9 years in group 3. The significant decrease in visual acuity in group 3 (28 eyes, 35.9%) was significantly higher than that in group 1 (15 eyes, 18.1%, p = 0.01) or group 2 (6 eyes, 20.7%, p = 0.03). Only vitreous hemorrhage showed a significantly higher incidence in groups 2 and 3 than in group 1 (p = 0.02). Multivariate regression analysis revealed that female sex and lower glycosylated hemoglobin were significantly associated with a protective effect on development of nephropathy. CONCLUSIONS: In the clinical setting, many patients with PRP-requiring diabetic retinopathy develop nephropathy an average of 8 to 9 years after PRP. Male sex and higher glycosylated hemoglobin could be risk factors of nephropathy.
Diabetes Mellitus, Type 1
;
Diabetes Mellitus, Type 2
;
Diabetic Nephropathies
;
Diabetic Retinopathy
;
Diagnosis
;
Electronic Health Records
;
Female
;
Hemoglobin A, Glycosylated
;
Humans
;
Incidence
;
Light Coagulation
;
Male
;
Prognosis
;
Retinal Diseases
;
Retrospective Studies
;
Risk Factors
;
Seoul
;
Visual Acuity
;
Vitreous Hemorrhage
5.Lateral Ventricular Meningioma Presenting with Intraventricular Hemorrhage
Ji Soo MOON ; Seung Heon CHA ; Won Ho CHO
Brain Tumor Research and Treatment 2019;7(2):151-155
A 35-year-old female visited emergency department for a sudden onset of headache with vomiting after management for abortion at local department. Neurological examination revealed drowsy mentality without focal neurological deficits. CT showed 3.2×3.4 cm hyperdense intraventricular mass with intraventricular hemorrhage. The intraventricular hemorrhage was found in lateral, 3rd, and 4th ventricles. MRI showed well enhancing intraventricular mass abutting choroid plexus in the trigone of the right lateral ventricle. CT angiography showed tortuous prominent arteries from choroidal artery in tumor. Her neurological status deteriorated to stupor and contralateral hemiparesis during planned preoperative workup. Urgent transtemporal and transcortical approach with decompressive craniectomy for removal of intraventricular meningioma with hemorrhage was done. Grossly total removal of ventricular mass was achieved. Pathological finding was meningotheliomatous meningioma of World Health Organization (WHO) grade I. The patient recovered to alert mentality and no motor deficit after intensive care for increased intracranial pressure. However, visual field defect was developed due to posterior cerebral artery territory infarction. The visual deficit did not resolve during follow up period. Lateral ventricular meningioma with spontaneous intraventricular hemorrhage in pregnant woman is very uncommon. We report a surgical case of lateral ventricular meningioma with rapid neurological deterioration for intraventricular hemorrhage.
Adult
;
Angiography
;
Arteries
;
Choroid
;
Choroid Plexus
;
Critical Care
;
Decompressive Craniectomy
;
Emergency Service, Hospital
;
Female
;
Follow-Up Studies
;
Fourth Ventricle
;
Headache
;
Hemorrhage
;
Humans
;
Infarction
;
Intracranial Pressure
;
Lateral Ventricles
;
Magnetic Resonance Imaging
;
Meningioma
;
Neurologic Examination
;
Paresis
;
Posterior Cerebral Artery
;
Pregnancy
;
Pregnant Women
;
Stupor
;
Visual Fields
;
Vomiting
;
World Health Organization
6.Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort.
Ko Eun KIM ; Pil Sung YANG ; Eunsun JANG ; Sungjin KIM ; Boyoung JOUNG
Yonsei Medical Journal 2019;60(1):65-72
PURPOSE: Antithrombotic therapy could be related with nuisance bleeding. This study investigated whether vitreous hemorrhage (VH) is associated with specific types of antithrombotic medication in patients with atrial fibrillation (AF). MATERIALS AND METHODS: In the Korean National Health Insurance Service National Sample Cohort, we identified 9352 antiplatelet/anticoagulant-treated AF patients. The occurrence of VH was compared between warfarin (n=1493) and a propensity score (PS)-matched antiplatelet group (n=1493) and between warfarin (n=1493) and a PS-matched warfarin+antiplatelet group (n=1493). RESULTS: The outcomes of VH were lower in the warfarin than in the matched antiplatelet (1.45 vs. 3.72 events/1000 patient-years) and matched warfarin+antiplatelet groups (1.45 vs. 6.87 events/1000 patient-years). Compared with warfarin, the risk of VH increased with antiplatelet [adjusted hazard ratio (aHR) 3.90; 95% confidence interval (CI) 1.22–12.4, p=0.022] and warfarin+antiplatelet agents (aHR 4.39, 95% CI 1.74–11.2, p=0.002). Compared with warfarin only, warfarin+antiplatelet agents increased the risk of VH in patients ≥65 years, regardless of gender and hypertension. The risk of VH was significantly higher with dual antiplatelet therapy (aHR: 5.02, 95% CI: 1.56–16.2, p=0.007) or in dual (aHR: 5.02, 95% CI: 1.74–14.5, p=0.003) or triple therapy using warfarin and antiplatelet agents than with warfarin monotherapy (aHR: 6.12, 95% CI: 1.76–21.3, p=0.004). CONCLUSION: Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Considering the low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplatelet agents should be avoided to prevent VH in AF patients.
Atrial Fibrillation*
;
Cohort Studies*
;
Hemorrhage
;
Humans
;
Hypertension
;
National Health Programs*
;
Platelet Aggregation Inhibitors
;
Propensity Score
;
Stroke
;
Vitreous Hemorrhage*
;
Warfarin
7.Hemorrhagic Moyamoya Disease : A Recent Update
Miki FUJIMURA ; Teiji TOMINAGA
Journal of Korean Neurosurgical Society 2019;62(2):136-143
Moyamoya disease (MMD) is a progressive cerebrovascular disease with unknown etiology, characterized by bilateral stenoocclusive changes at the terminal portion of the internal carotid artery and an abnormal vascular network formation at the base of the brain. MMD has an intrinsic nature to convert the vascular supply for the brain from internal carotid (IC) system to the external carotid (EC) system, as indicated by Suzuki’s angiographic staging. Insufficiency of this ‘IC-EC conversion system’ could result not only in cerebral ischemia, but also in intracranial hemorrhage from inadequate collateral anastomosis, both of which represent the clinical manifestation of MMD. Surgical revascularization prevents cerebral ischemic attack by improving cerebral blood flow, and recent evidence further suggests that extracranial-intracranial bypass could powerfully reduce the risk of re-bleeding in MMD patients with posterior hemorrhage, who were known to have extremely high re-bleeding risk. Although the exact mechanism underlying the hemorrhagic presentation in MMD is undetermined, most recent angiographic analysis revealed the characteristic angio-architecture related to high re-bleeding risk, such as the extension and dilatation of choroidal collaterals and posterior cerebral artery involvement. We sought to update the current management strategy for hemorrhagic MMD, including the outcome of surgical revascularization for hemorrhagic MMD in our institute. Further investigations will clarify the optimal surgical strategy to prevent hemorrhagic manifestation in patients with MMD.
Angiography
;
Brain
;
Brain Ischemia
;
Carotid Artery, Internal
;
Cerebrovascular Circulation
;
Cerebrovascular Disorders
;
Choroid
;
Dilatation
;
Hemorrhage
;
Humans
;
Intracranial Hemorrhages
;
Moyamoya Disease
;
Posterior Cerebral Artery
8.Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
Yoo Ri CHUNG ; Kyoung Hwa HA ; Hyeon Chang KIM ; Sang Jun PARK ; Kihwang LEE ; Dae Jung KIM
Diabetes & Metabolism Journal 2019;43(5):640-648
BACKGROUND: To investigate the effects of dipeptidyl peptidase-4 inhibitor (DPP4i) as add-on medications to metformin on progression of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus, compared with sulfonylurea (SU) or thiazolidinedione (TZD). METHODS: We identified 4,447 patients with DPP4i, 6,136 with SU, and 617 with TZD in addition to metformin therapy from the database of Korean National Health Insurance Service between January 2013 and December 2015. Cox proportional hazards regression models were used to calculate hazard ratios (HRs) for DR progression. The progression of DR was defined by the procedure code of panretinal photocoagulation, intravitreal injection or vitrectomy; or the addition of diagnostic code of vitreous hemorrhage, retinal detachment, or neovascular glaucoma. RESULTS: The age and sex-adjusted HR of DR progression was 0.74 for DPP4i add-on group compared with SU add-on group (95% confidence interval [CI], 0.62 to 0.89). This lower risk of DR progression remained significant after additional adjustments for comorbidities, duration of metformin therapy, intravitreal injections and calendar index year (HR, 0.80; 95% CI, 0.66 to 0.97). CONCLUSION: This population-based cohort study showed that the use of DPP4i as add-on therapy to metformin did not increase the risk of DR progression compared to SU.
Cohort Studies
;
Comorbidity
;
Diabetes Mellitus, Type 2
;
Diabetic Retinopathy
;
Dipeptidyl-Peptidase IV Inhibitors
;
Glaucoma, Neovascular
;
Humans
;
Hypoglycemic Agents
;
Intravitreal Injections
;
Light Coagulation
;
Metformin
;
National Health Programs
;
Retinal Detachment
;
Vitrectomy
;
Vitreous Hemorrhage
9.The Effects of Long-term Hemodialysis on Visual Acuity and Central Macular Thickness in Diabetic Retinopathy Patients
Jun Hyun LIM ; Chang Zoo KIM ; Seung UK LEE ; Sang Joon LEE
Journal of the Korean Ophthalmological Society 2019;60(11):1064-1071
PURPOSE: To investigate the changes of visual acuity and central macular thickness (CMT) in patients with diabetic retinopathy (DR) receiving long-term hemodialysis (HD). METHODS: From January 1, 2008, to December 31, 2018, the medical records of patients who were diagnosed with DR receiving HD three times a week for ≥18 months due to chronic kidney disease (CKD) were analyzed. Among them, patients diagnosed with DR 6 months before the start of HD were included. Patients with vitreous hemorrhage (VH) affecting visual acuity (VA), other retinal diseases, and cataract surgery after HD were excluded. The VA and CMT before HD and at 1, 3, 6, 12, and 18 months after HD were analyzed. RESULTS: Of the 222 eyes of 111 patients who were diagnosed with DR and received HD for CKD due to diabetes, 174 eyes with DR diagnosed after starting HD were excluded. Ten eyes with VH before starting HD, two eyes with epiretinal membrane, and four eyes with cataract surgery after starting HD were also excluded. Thirty-two eyes of 18 patients were included. The mean age of the patients was 53.71 ± 9.25 years. Twenty-four males and eight female patients were included in the study. The mean logMAR VA improved significantly from 0.36 ± 0.28 before starting HD to 0.26 ± 0.27 at 18 months after starting HD (p = 0.002). The mean CMT was significantly decreased from 307.12 ± 89.52 µm before starting HD to 279.71 ± 61.75 µm at 12 months after starting HD (p = 0.02). CONCLUSIONS: In patients with DR who underwent long-term HD, CMT decreased and VA improved, when compared with these parameters before HD.
Cataract
;
Diabetic Retinopathy
;
Epiretinal Membrane
;
Female
;
Humans
;
Macular Edema
;
Male
;
Medical Records
;
Renal Dialysis
;
Renal Insufficiency, Chronic
;
Retinal Diseases
;
Visual Acuity
;
Vitreous Hemorrhage
10.Choroidal Neovascularization in a Patient with Best Disease
Jae Uk JUNG ; Yu Min KIM ; Yong Koo KANG ; Dong Ho PARK ; Jae Pil SHIN
Journal of the Korean Ophthalmological Society 2019;60(8):808-815
PURPOSE: To report a case of choroidal neovascularization in a Best disease patient treated with intravitreal bevacizumab injection and followed up with optical coherence tomography angiography (OCTA). CASE SUMMARY: A 20-year-old female visited our clinic with decreased visual acuity of the left eye for 6 months. On optical coherence tomography (OCT), subretinal fluid and hyperreflective subretinal clumps were observed in the macula of the right eye. Subretinal hemorrhage and subretinal fluid were observed in the left eye. Choroidal neovascularization in the left eye was observed using OCTA, fluorescein angiography, and indocyanine green angiography. A full-field electroretinogram was normal in both eyes, but an electrooculogram revealed that the Arden ratio was 1.564 in the right eye and 1.081 in the left eye. Intravitreal bevacizumab injection was performed in the left eye. At 6 months after the intravitreal injection, the best-corrected visual acuity of the left eye had recovered to 20/20. OCT revealed that subretinal fluid reduced and choroidal neovascularization was stable. After 12 months, visual acuity of the left eye was maintained at 20/20, but OCTA revealed that choroidal neovascularization had increased. CONCLUSIONS: Choroidal neovascularization associated with Best disease can improve by intravitreal bevacizumab injection, and the changes in choroidal neovascularization can be followed using OCTA.
Angiography
;
Bevacizumab
;
Choroid
;
Choroidal Neovascularization
;
Electrooculography
;
Female
;
Fluorescein Angiography
;
Hemorrhage
;
Humans
;
Indocyanine Green
;
Intravitreal Injections
;
Subretinal Fluid
;
Tomography, Optical Coherence
;
Visual Acuity
;
Vitelliform Macular Dystrophy
;
Young Adult


Result Analysis
Print
Save
E-mail